BACKGROUND
Izalontamab brengitecan (iza-bren) is a first-in-class bispecific antibody-drug conjugate targeting epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3) and has shown antitumour activity in EGFR-mutated non-small-cell lung cancer (NSCLC). We compared iza-bren with plati...
Shao-Dong Hong, Ting Zhou, Xue Hou et al.· The Lancet· 0 citations
BACKGROUND
Ruzaltatug rezetecan is a novel HER3-directed antibody-drug conjugate that has shown promising antitumour activity and manageable safety in pretreated EGFR-.mutated non-small-cell lung cancer (NSCLC) in a phase 1 trial. We aimed to compare the efficacy and safety of ruzaltatug rezetecan with chemotherapy in...
Chong-Rui Xu, Yan Zhang, G. Lin et al.· The Lancet· 1 citation
Findings support sutetinib as a potential treatment option for this molecularly heterogeneous population of adults with locally advanced or metastatic NSCLC harboring uncommon EGFR mutations and demonstrate clinically meaningful antitumor activity with a manageable safety profile.
Feng-Ying Wu, Wei Zhang, Yan-Qiu Zhao et al.· Journal of Thoracic Oncology· 0 citations